Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Giant Cell Arteritis: SELECT-GCA
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary) ; Corticosteroid; Prednisolone
- Indications Giant cell arteritis
- Focus Registrational; Therapeutic Use
- Acronyms SELECT-GCA
- Sponsors AbbVie; AbbVie Germany
- 18 Apr 2024 According to AbbVie media release, full results of the study will be presented at a future medical meeting.
- 18 Apr 2024 Primary endpoint has been met. (Percentage of Participants Achieving Sustained Remission)
- 18 Apr 2024 Results published in the Media Release